Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression

Prostate cancer (PCa) is the second leading cause of cancer death in men in America, and there are no curative options for metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (DTX) has been used as a standard chemotherapy for the mCRPC. However, resistance to DTX is a significant clin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncogene
Hlavní autoři: Hu, Linyi, Sun, Yin, Luo, Jie, He, Xiang, Ye, Meihua, Li, Gonghui, Zhang, Yong, Bai, Jian, Zhang, Dahong, Chang, Chawnshang
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044111/
https://ncbi.nlm.nih.gov/pubmed/31748715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-019-1070-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky